H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a promising small-cap growth stock by hedge funds, despite a recent price target reduction by H.C. Wainwright analyst Raghuram Selvaraju from $120 to $100 while maintaining a Buy rating [1][6]. Financial Performance - For fiscal Q4 2025, Soleno reported quarterly revenue of $91.73 million, exceeding estimates by $3.18 million. The earnings per share (EPS) of $0.8 also surpassed consensus expectations by $0.09 [2]. - The revenue reflects less than nine months of commercial sales from the early adoption of VYKAT XR [2]. Market Outlook - The analyst projects a strong commercial outlook for Soleno, anticipating that VYKAT XR will capture 20% of the total market share for Prader-Willi syndrome [3]. - At the end of Q4 2025, there were 859 active patients on VYKAT XR treatment, an increase from 764 in Q3 [3]. Company Profile - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, including Prader-Willi Syndrome [3].